Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > New Deal for Adstiladrin

<< Previous

Bullboard Posts

Next >>

Comment by ScienceFirston Aug 26, 2023 6:01pm

265 Views

Post# 35606927

RE:RE:New Deal for Adstiladrin

And that's just for the US.

Royalty will pay $300 million up front and $200 million in a potential milestone payment tied to Ferring meeting certain manufacturing goals by 2025.

New York City-based Royalty will receive 5.1% of net sales of Adstiladrin in the U.S. Upon payment of the milestone, the royalty will jump to 8%. The deal sustains royalty payments through the early-to-mid 2030s, the companies said.

Note that TLT has also focused on regional rights.

<< Previous

Bullboard Posts

Next >>

Mid-year update: Charting GameSquare’s sharp business growth